New Haven, CT – According to filings with the U.S. Securities and Exchange Commission, Cybrexa is raising $43,224,407.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Per Hellsund played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cybrexa
Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex platform. The Companys lead candidate, CBX-12, an alphalex-exatecan conjugate, is expected to enter Phase I in 2021 in advanced solid tumors. Cybrexa also has other preclinical toxin conjugate programs as well as synthetic lethality programs. Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies.

To learn more about Cybrexa, visit http://www.cybrexa.com/

Contact:
Per Hellsund, Chief Executive Officer
860-876-0380
per.hellsund@cybrexa.com
https://www.linkedin.com/in/per-hellsund-860b20b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved